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Results: Results: After adjustment for baseline gastric cancer incidence, individuals with eradication of H pylori infection had a lower incidence of gastric cancer than those who did not receive eradication therapy (pooled incidence rate ratio, 0.53; 95% confidence interval (CI), 0.44-0.64). There was little heterogeneity among studies.
Baseline gastric cancer incidence modified the benefit of H pylori eradication (P=.037 for interaction); the incidence rate ratio of gastric cancer decreased in a non-linear fashion with increasing baseline incidence of gastric cancer (P=.018, in comparison with the linear model). The benefit also modestly increased with age (P=.023 for interaction), but this might be due to correlation between age and baseline gastric cancer incidence. Eradication provided significant benefit for asymptomatic infected individuals (pooled incidence rate ratio, 0.62; 95% CI, 0.49-0.79) and individuals after M A N U S C R I P T
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INTRODUCTION
Gastric cancer is a major global health threat [1] [2] [3] and is the third leading cause of cancer deaths worldwide causing an estimated more than 720,000 deaths per year globally. 4 H pylori is the most important etiologic factor for gastric cancer. H pylori infects approximately 50% of the global population, 4 and it is estimated that 89% of non-cardia gastric cancers, which accounts for 78% of gastric cancer cases, are attributed to H pylori infection. 5, 6 H pylori promotes gastric carcinogenesis through multiple mechanisms. H pylori causes chronic gastric inflammation that may progress to the precancerous changes of atrophic gastritis and intestinal metaplasia. The risk of gastric cancer increases in relation to the severity and extent of those precancerous changes. 7 Chronic H pylori infection may also contribute to gastric mucosal genetic instability 8 by reducing gastric acid secretion (hypochlorhydria), which can promote the growth of gastric microbiome that processes dietary components into carcinogens. 7 Eradication of H pylori may result in resolution of gastric inflammation, halt the progression of gastric mucosal damage, prevent further M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 7 There has been increasing interest in mass H pylori eradication to prevent gastric cancer. However, the benefit of eradication varies in relation to baseline gastric cancer risk, 10 which varies widely across regions and populations, 4 and the extent to which mass H pylori eradication will affect gastric cancer incidence remains unclear.
A recent meta-analysis combining six randomized controlled trials (RCTs) conducted in asymptomatic infected individuals reported that H pylori eradication reduced the risk of gastric cancer in Asians, but the effect might not be generalizable to areas with a lower incidence rate of gastric cancer. 10 However, that study used the risk (i.e., the number of gastric cancer cases at the end of follow-up divided by the number of individuals at baseline) for the intervention and comparison groups in each study to conduct meta-analysis and expressed the results with risk ratios; this approach does not take into account differences in follow-up duration and loss to follow-up.
Controversies also exist regarding whether eradication could still provide protection against gastric cancer once atrophic gastritis and/or intestinal metaplasia develops.
One RCT conducted in asymptomatic infected individuals showed that eradicating H pylori reduced the incidence of gastric cancer only in subjects without premalignant gastric lesions but not in those with atrophic gastritis, suggesting there may be a point of no return beyond which irreversible molecular changes renders eradication ineffective or less effective in preventing progression to cancer. A better understanding of the size of the benefit to be expected following eradicating H pylori in populations with differing levels of gastric cancer risk is crucial in deciding whether and how mass eradication of H pylori should be implemented. We conducted a systematic review and meta-analysis of RCTs and cohort studies conducted in both asymptomatic H pylori carriers (i.e., primary prevention) and in individuals undergoing endoscopic resection of early gastric cancer (i.e., tertiary prevention) to investigate the association between H pylori eradication and gastric cancer incidence.
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METHODS
Search strategy and selection criteria
We performed a systematic review in accordance with PRISMA (Preferred 
Data extraction and assessment for study quality
Two investigators (THC and CKC) independently reviewed full manuscripts of eligible studies and extracted information into an electronic database, including author, publication year, country where the study was conducted, study design, sample size, duration of follow-up, participants' characteristics, inclusion and exclusion criteria, diagnostic criteria for H pylori infection, the number of subjects in both intervention and comparison groups, the number of incident gastric cancers in both intervention and comparison groups, the modality used during endoscopic resection for early gastric cancer in the tertiary prevention trials, and the final outcomes. The same reviewers independently evaluated the risk of bias of included RCTs with the Cochrane risk of bias tool 16 and assessed the quality of cohort studies with the Newcastle-Ottawa scale. 17 Disagreement was resolved by joint review of the manuscript to reach consensus. When multiple articles for a single study were found, we used data from the latest publication.
Data synthesis and analysis
To account for differences in follow-up durations, we used incidence rate of gastric cancer for conducting meta-analysis. Random effects models were used for all meta-analyses to account for potential heterogeneity among studies. Two
approaches were undertaken for data synthesis. We first conducted random-effects meta-analysis proposed by DerSimonian and Laird with the use of the incidence rate ratio as the measure of effect size. 18 Pre-planned subgroup meta-analyses were undertaken for studies of low, intermediate, and high baseline incidence of gastric cancer (defined by the tertiles of incidence rates in the groups not receiving eradication in the included studies). Subgroup analyses were also conducted with regard to study designs (i.e., RCT or cohort study) and clinical scenarios (i.e., asymptomatic H pylori carriers or patients with prior endoscopic resection of gastric cancer). We used meta-regression to evaluate whether incidence rate ratio differed by tertiles of baseline cancer incidence, study designs, and clinical scenarios.
Potential small study bias was evaluated by funnel plots and by Egger's test 19 and
Begg's test. 20 Heterogeneity was evaluated by I 2 and Cochran's Q. 21 Second, as traditional meta-analysis can introduce bias when using continuity corrections for studies with no event in one of the study arms, 22 we also conducted meta-analysis using generalized linear mixed models. 23 We used random effect Poisson regression to model the effect of H pylori eradication on gastric cancer incidence with the number of cases as the outcome and the person-year as the offset in the model. The study-by-treatment interaction was included as the random effect in the regression model.
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We further evaluated whether the effect of H pylori eradication on subsequent gastric cancer incidence was modified by the baseline gastric cancer incidence with the inclusion of interaction terms between the treatment and baseline gastric cancer incidence as fixed effects in the model; baseline gastric cancer incidence was treated as a continuous variable in the analysis because the incidence rate was apparently a continuous variable and categorizing a continuous variable might result in loss of information. 24 This approach also enabled us to assess how the benefit of eradication changed linearly/nonlinearly with varying baseline gastric cancer incidence. If significant interaction between treatment and baseline gastric cancer incidence existed, the relation between incidence rate ratio and baseline cancer incidence was modeled using restricted cubic splines with three knots to explore potential non-linear relationship as well as the threshold value for a significant treatment effect. Likewise, we examined whether study design (i.e., RCT vs. cohort), clinical scenario (i.e., asymptomatic infected individuals vs. individuals after endoscopic resection of early gastric cancer), demographic characteristics (i.e., age and gender), and follow-up duration would modify the effect of H pylori eradication on subsequent gastric cancer incidence. All p values were two-sided, and p<0.05 was considered to indicate statistical significance.
For sensitivity analysis, we first excluded studies that were published as abstracts.
Second, we repeated the analysis with the exclusion of each study in turn to evaluate whether any study had excessive influence on the results of our meta-analysis.
All meta-analyses were conducted using the statistical software package Stata 14 (StataCorp, College Station, Texas, US).
RESULTS
Literature search
We identified 8,061 articles for review of title and abstract ( Figure 1 ). 25, 36 The mean age at enrollment ranged from 42 to 63 years in all studies except a cohort study
Except two studies 26, 28 reported in the abstract form, all included studies were considered as high or moderate quality (Appendix Table 1 per 100,000 person-years); the pooled incidence rate ratio was 0.80 (95% CI:
Meta-regression analysis reaffirmed that the quantitative benefit of H pylori eradication was greater in studies with higher baseline incidence rates of gastric cancer. Using studies of the lowest tertile of baseline incidence as reference, the pooled incidence rate ratios for eradication vs. non-eradication were reduced by 43.5% (95% CI: 4.3%-66.6%) in the highest tertile and by 38.4% (95% CI:
1.7%-61.4%) in the intermediate tertile, respectively.
Subgroup analyses according to different clinical scenarios (Figure 3) showed that the quantitative benefit of eradication seemed greater among individuals after endoscopic resection of gastric cancers (pooled incidence rate ratio: 0.46, 95% CI: 
Mixed-effect Poisson regression meta-analysis
Results of the mixed-effect Poisson regression meta-analysis were similar with those of the traditional meta-analyses. Individuals who received H pylori eradication had a lower incidence of gastric cancer than those who did not receive eradication therapy; the pooled incidence rate ratio was 0.53 (95% CI: 0.44-0.64) with little heterogeneity across studies ( Table 2 , model 1). Interaction analyses showed that baseline gastric cancer incidence significantly modified the benefit of eradication (model 2); the incidence rate ratio of gastric cancer decreased in a non-linear fashion with rising baseline incidence rate (p=0.018 in comparison with linear model) ( Figure   4 ). The upper 95% confidence interval of incidence rate ratio for eradication decreased to below 1 when baseline gastric cancer incidence exceeded 150 per 100,000 person-years, and the incidence rate ratio continued to decrease with rising baseline incidence up to around 1,200 per 100,000 person-years and then stabilized.
With exclusion of two studies 25, 39 that did not provide information on age of participants, age also seemed to modestly modify the benefit of eradication (model 5, p-value interaction=0.023); the incidence rate ratio decreased by 3% (95% CI:
0%-5%) with every one year increase in the median age of participants. However, the interaction between age and eradication became non-significant (p-value interaction=0.25) when interaction between eradication and baseline incidence was also entered into the model; therefore, the impact of age on the effect of eradication might be due to the fact that studies with older patients tended to have higher baseline gastric cancer incidence. The benefit conferred by H pylori eradication did not differ by study design, clinical scenario, the percentage of male subjects, or follow-up duration (model 3, 4, 6 or 7). No material difference in results was noted in pre-specified sensitivity analyses, and no individual study had excessive influence on the summary estimate.
DISCUSSION
This meta-analysis is the first to evaluate the association between H pylori eradication and the incidence of gastric cancer across different levels of baseline gastric cancer risk and in different clinical scenarios. Our results support the concept that H pylori eradication effectively reduces the incidence of gastric cancer, and the magnitude of the protective effect is greater among individuals with higher baseline gastric cancer risk.
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In the two previous meta-analyses that also evaluated the effect of H pylori eradication on gastric cancer prevention, the estimated relative risks were closer to 1 was similar to those from previous meta-analyses but with a narrower confidence interval. We were also able to identify that H pylori eradication provided even greater benefit among high-risk individuals. Taken together, our meta-analysis has a wider evidence base and greater statistical power with more precise estimates; therefore, 19 19 our results should better reflect the full spectrum of the potential benefit of implementing mass H pylori eradication for gastric cancer prevention.
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The novel finding that the protective effect of H pylori eradication increased along with increasing gastric cancer incidence argues against an absolute The notable finding that H pylori eradication confers greater protection against gastric cancer for individuals with a higher baseline cancer risk might be attributed to the phenomenon that the risk of gastric cancer increases exponentially over time in those high-risk individuals. 49 Therefore, the difference in subsequent cancer risk between eradicated and non-eradicated groups in an individual study is likely to be greater if eradication is provided when the cancer risk has increased to a higher level, and studies on high-risk individuals might have superior statistical power than studies on low-risk individuals. 50 Indeed, even with relatively limited sample size and follow-up duration, the benefit of H pylori eradication was evident in the included M A N U S C R I P T 21 21 studies that assessed individuals undergoing endoscopic resection of early gastric cancer, who belonged to the subset of individuals at the highest risk of gastric cancer. 51 Without effective preventive measures, the current high incidence of gastric cancer is projected to remain stable or even increase by 2030. 4 The International Agency for
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Research on Cancer has indicated the urgent need for effective preventive measures and for a critical assessment of H pylori eradication as a preventive strategy. 52 Our results support that mass H pylori screening and eradication is a viable preventive strategy and should be implemented in high-risk populations/areas, especially in those with an incidence rate higher than 150/100,000 person-years. While we found that the protective effect of H pylori eradication is less conspicuous in low-incidence individuals, this finding does not argue against implementing H pylori eradication for gastric cancer prevention in low-incidence populations. Overall, our results clearly show that eradication protects against gastric cancer; the 95% confidence interval of the pooled incidence rate ratio crossing one when incidence rate is below 150/100,000 person-years reflects limited statistical power due to smaller effect size and relative paucity of evidence from low-incidence areas. Furthermore, H pylori infection can be reliably identified with non-invasive methods and eradicated with an overall success rate above 90% 53, 54 through selecting a regimen with or without M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 22 22 clarithromycin according to the 15%-20% threshold of macrolide resistance in a specific population. 9 In light of the unequivocal benefit of H pylori eradication, future long-term placebo controlled trials for high-risk population would be unethical. How H pylori eradication should be implemented in low-incidence populations/areas should be further evaluated. For instance, in areas with intrinsically lower rates of gastric cancer (e.g., much of Europe and North America), there are high-risk populations (such as immigrants from high-risk areas) and thus eradication may need to be focused; simulation studies have shown that such a strategy would be cost-effective in the long run.
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Our meta-analysis addresses the limitations of existing research and has several strengths. Most of previous studies were underpowered; it is estimated that even in a high-risk population with an annual incidence rate of 200 per 100,000 person-years, 17,625 individuals per group with a follow-up duration of 10 years are need for an RCT to demonstrate a 50% reduction in gastric cancer incidence with eradication against placebo. 49 Our meta-analysis evaluated the association between H pylori Our study also has some limitations. First, all but two of the included studies were conducted in East Asia; therefore, whether the results can be extrapolated to other high-risk areas remains unclear. Second, the presence and severity of atrophic gastritis and intestinal metaplasia were not uniformly assessed and reported in the included studies (i.e., they lacked risk stratification: Appendix Table 3 ). Therefore, it remains speculative to translate the magnitude of benefit for subjects with early gastric cancer to those who have precancerous changes in their gastric mucosae. cancer was characteristic for its rapid progression with a preclinical detectable phase of only about 1.4 years. 56 Without treatment, gastric cancers early in stage will eventually progress to the symptomatic stage in a short time period such that the difference between these two approaches would be minimal. This interpretation was also supported by our subgroup analysis that showed no significant difference between the different clinical scenarios. Lastly, this meta-analysis was conducted using summary statistics rather than individual data. The modest interaction between age and H pylori eradication may be influenced by collinearity between age and baseline gastric cancer incidence. However, there might be some covariates that could influence the effect of eradication, but were not reported and thus could not be adjusted. Access to and examination of data from individual participants should allow further identification and control of potential confounding factors.
In conclusion, our meta-analysis confirmed that H pylori eradication is associated with a reduction of the incidence of gastric cancer. Although the level of benefit varies, it presents across all levels of baseline gastric cancer risk. H pylori eradication may be the most viable strategy for gastric cancer prevention. 26 and Nakagawa et al 40 excluded due to lack of information).
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e Percentage of male subjects in individual studies (Saito et al 26 and Nakagawa et al 40 excluded due to lack of information).
f Median follow-up duration in individual studies. 
